What 14 Analyst Ratings Have To Say About Sarepta Therapeutics

1 day ago · SRPT Sarepta Therapeutics Inc. $119.33 0.42% ... Guggenheim: Raises: Buy: $150.00: $148.00: Brian Skorney: Baird: ... Sarepta Therapeutics Inc is a biotechnology …

42%
OFF

What 14 Analyst Ratings Have To Say About Sarepta Therapeutics

2 weeks from now

1 day ago · SRPT Sarepta Therapeutics Inc. $119.33 0.42% ... Guggenheim: Raises: Buy: $150.00: $148.00: Brian Skorney: Baird: ... Sarepta Therapeutics Inc is a biotechnology …

benzinga.com

$150
OFF

Sarepta Price Target Raised To $150 From $148 At Guggenheim

2 weeks from now

Nov 7, 2024 · Guggenheim raised the firm’s price target on Sarepta (SRPT) to $150 from $148 and keeps a Buy rating on the shares. Elevidys and exon-skipping franchise sales were above …

nasdaq.com

$200.00
OFF

Sarepta Therapeutics (NASDAQ:SRPT) Earns "Buy" Rating From

2 weeks from now

2 days ago · Robert W. Baird cut their price target on Sarepta Therapeutics from $200.00 to $193.00 and set an "outperform" rating for the company in a report on Thursday, November …

marketbeat.com

$148.00
OFF

Guggenheim Issues Positive Forecast For Sarepta Therapeutics …

2 weeks from now

Nov 10, 2024 · Sarepta Therapeutics (NASDAQ:SRPT – Free Report) had its price target raised by Guggenheim from $148.00 to $150.00 in a research report released on Thursday,Benzinga …

mayfieldrecorder.com

$183.00
OFF

Guggenheim Starts Sarepta Therapeutics (SRPT) At Buy

2 weeks from now

Dec 26, 2019 · Guggenheim analyst Whitney Ijem initiates coverage on Sarepta Therapeutics (NASDAQ: SRPT) with a Buy rating and a price target of $183.00.For an analyst ratings …

streetinsider.com

23%
OFF

SRPT Stock Rises 23% In A Year: Time To Buy, Hold Or Sell?

2 weeks from now

Jan 6, 2025 · Estimates for Sarepta Therapeutics’ 2024 earnings per share (EPS) have risen from $1.48 to $2.17 in the past 60 days. Over the same timeframe, EPS estimates for 2025 have …

zacks.com

23%
OFF

SRPT Stock Rises 23% In A Year: Time To Buy, Hold Or Sell? - Yahoo …

2 weeks from now

Jan 6, 2025 · Shares of Sarepta Therapeutics SRPT have risen 23% in the past year, significantly outperforming the industry’s 15.7% decline, as shown in the chart below. During this …

yahoo.com

$158.87
OFF

A Glimpse Into The Expert Outlook On Sarepta Therapeutics

2 weeks from now

Dec 19, 2024 · Analysts have recently evaluated Sarepta Therapeutics and provided 12-month price targets. The average target is $158.87, accompanied by a high estimate of $205.00 and …

nasdaq.com

17%
OFF

Has Sarepta Therapeutics Become A No-Brainer Stock Buy After …

2 weeks from now

Jul 4, 2024 · Sarepta Therapeutics (SRPT-1.17%) stock has been flying of late, as the company got some great news from the FDA that has the potential to be a game changer for its …

fool.com

$11.38
OFF

Arrowhead, Sarepta Launch On A Whopping $11.38 Billion Deal

2 weeks from now

Nov 26, 2024 · How Avidity Biosciences Just Dropped The Hammer On Sarepta Therapeutics; Stocks To Watch: Sarepta Therapeutics Sees Relative Strength Rating Rise To 91; Stocks …

investors.com

34%
OFF

Sarepta Therapeutics (SRPT) Stock Forecast & Price Target

2 weeks from now

Sarepta Therapeutics (SRPT) has been analyzed by 35 analysts, with a consensus rating of Buy. 34% of analysts recommend a Strong Buy, 54% recommend Buy, 9% suggest Holding, 0% …

public.com

70%
OFF

Guggenheim Likes Sarepta In Premarket Analyst Action - Seeking …

2 weeks from now

Nov 1, 2019 · Sarepta Therapeutics (NASDAQ:SRPT) ... initiated with Buy rating and $43 (70% upside) price target at Guggenheim. Y-mAbs Therapeutics (NASDAQ: ...

seekingalpha.com

23%
OFF

SRPT Stock Rises 23% In A Year: Time To Buy, Hold Or Sell?

2 weeks from now

Jan 6, 2025 · Shares of Sarepta Therapeutics SRPT have risen 23% in the past year, ... Management is also on track to start a clinical study on another gene therapy, SRP-9005, for …

nasdaq.com

14%
OFF

SRPT Inks $11B Licensing Deal With Arrowhead For Rare Gene …

2 weeks from now

Nov 27, 2024 · Shares of Sarepta Therapeutics (SRPT Quick Quote SRPT - Free Report) rose nearly 14% on Tuesday after announcing that it has entered into an exclusive global licensing …

zacks.com

$11
OFF

SRPT Inks $11B Licensing Deal With Arrowhead For Rare Gene

2 weeks from now

Nov 27, 2024 · Sarepta Therapeutics currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here . 7 Best Stocks for the Next 30 Days

nasdaq.com

FAQs about What 14 Analyst Ratings Have To Say About Sarepta Therapeutics Coupon?

Is Sarepta Therapeutics a good stock to invest in?

Sarepta Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 16 buy ratings, 2 hold ratings, and no sell ratings. This indicates strong analyst interest in the stock, with 12 research reports in the past 90 days. ...

Should you buy Sarepta (SRPT)?

The disconnect between Sarepta’s current valuation and its stock price suggests substantial room for growth, reinforcing the recommendation for investors to consider buying SRPT shares. In another report released yesterday, TD Cowen also maintained a Buy rating on the stock with a $203.00 price target. ...

What is the average rating score for Sarepta Therapeutics?

The company's average rating score is 2.89. Sarepta Therapeutics has received a consensus rating of Moderate Buy. The company has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock. ...

What was Sarepta Therapeutics' stock price on January 1st, 2024?

Sarepta Therapeutics' stock was trading at $96.43 on January 1st, 2024. Since then, SRPT shares have increased by 40.8% and is now trading at $135.78. ...

Is Sarepta a blockbuster gene therapy?

Since its commercial launch in June 2023, the gene therapy has demonstrated blockbuster potential. Though the therapy was initially approved in the country with a confined label for use in ambulatory DMD patients aged four to five years, it added more than $200 million to Sarepta’s top line in 2023. ...

Is Sarepta Therapeutics a no-brainer stock?

Has Sarepta Therapeutics Become a No-Brainer Stock Buy After This Recent FDA News? Previously, Sarepta's gene therapy treatment Elevidys was approved for only a limited number of Duchenne muscular dystrophy patients. Regulators, however, have expanded that range, and it can now be used to treat patients who are 4 and older. ...